Injection frequency of botulinum toxin A for spastic equinus: a randomized clinical trial. (20th November 2015)

• Record Type: Journal Article
• Authors: Hastings‐Ison, Tandy; Blackburn, Christine; Rawicki, Barry; Fahey, Michael; Simpson, Pam; Baker, Richard; Graham, Kerr
• Is Part Of: Developmental medicine & child neurology. Volume 58:Number 7(2016:Jul.)
• Page Start: 750
• Page End: 757
• Publication Date: 2015-11-20
• Subjects: Child development -- Periodicals; Pediatric neurology -- Periodicals; 616.8
• DOI: 10.1111/dmcn.12962
• Languages: English
• ISSNs: 0012-1622

Abstract

Abstract : Aim: We compared two botulinum toxin A (BoNT‐A) injection frequency regimens, 12‐monthly versus 4‐monthly, for spastic equinus in a randomized clinical trial. The primary outcome measure was passive ankle dorsiflexion. Method: Forty‐two ambulant children with spastic equinus, secondary to cerebral palsy (23 males and 19 females; mean age 3y 6mo, SD 13mo; GMFCS levels I [ n= 20], II [ n =19], III [ n =3]) were randomized to receive either 12‐monthly or 4‐monthly BoNT‐A injections to the calf, over a 26‐month period. Twenty‐one children had spastic hemiplegia, 21 children had spastic diplegia. A fixed 6U/kg dose of Botox was injected into the gastrocnemius muscle of both limbs in children with diplegia and the gastrocsoleus of the affected limb in children with hemiplegia, under mask anaesthesia. Results: Forty‐two children entered the trial with 21 participants randomized to each group. There were three withdrawals and two children received serial casting midway through the trial. There was no significant difference in passive dorsiflexion between 12‐monthly and 4‐monthly regimens ( p =0.41). There were also no significant between group differences on secondary outcome measures. There were no serious adverse events – the rate was 1.2 adverse events per child per year in the 12‐monthly group and 2.2 adverse events per child per year in the 4‐monthly group. Subgroup analysis revealed a significant difference in passive dorsiflexion between children with hemiplegia and diplegia ( p =0.01). Interpretation: There was no significant difference between 12‐monthly and 4‐monthly injection regimens on passive dorsiflexion or secondary outcome measures. BoNT‐A injections for spastic equinus may be recommended on a 12‐monthly basis. What this paper adds: Injection of botulinum toxin A (BoNT‐A) once each year was as effective as injection three times per year, for young children with cerebral palsy and spastic equinus. Children with spastic hemiplegia had different responses to those with spastic diplegia. Injections of BoNT‐A for spastic equinus may be recommended on a 12‐monthly basis. This article is commented on by Matthews on pages657–658 of this issue.